Vol. 17/No. 2 | Oncology Live®

February 03, 2016

Pacritinib, a JAK2/FLT3 inhibitor, is among the most promising of those emerging options for patients with myelofibrosis.

February 01, 2016

Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.

January 19, 2016

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

January 18, 2016

Disruptive technology abounds across a broad range of tumor types and clinicians throughout the spectrum of care will be learning about and adapting to new paradigms.

January 15, 2016

Mortality and morbidity both appear to be declining with the emergence of better antibiotics and growth factors, so hematologists are beginning to consider transplants for patients who were once considered too old or too sickly to endure anything as harsh as a stem cell transplant.

January 14, 2016

With technological advancements in genome sequencing, researchers are now gaining a more detailed picture of the genetic drivers of cervical cancer and the important role that the human papillomavirus, responsible for the vast majority of cervical cancer cases, plays in molding the genetic profile of this disease.

January 13, 2016

Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.

January 13, 2016

Questions remain in terms of how to optimally sequence and/or combine both targeted agents and immunotherapies in melanoma.

January 13, 2016

A substantial—and potentially growing—proportion of patients with non–small cell lung cancer are people who never, or only rarely, smoked.

January 08, 2016

There is an objectively rational and scientifically valid alternative to evaluate N-of-1 experiences, and there is a critical need for the continued development of such approaches, which the oncology community increasingly recognizes as a necessary step to replace the established but untenable randomized clinical trial paradigm.